Old drug, new target: can a common Anti-Inflammatory pill protect diabetic hearts?
NCT ID NCT05949281
Summary
This study is testing if adding a low daily dose of colchicine, an existing anti-inflammatory drug, to standard diabetes care can reduce inflammation and lower the risk of heart disease in people with long-standing Type 1 diabetes. About 100 participants, who already have or are at high risk for heart disease, will take either colchicine or a placebo pill daily for 6 to 12 months. Researchers will track markers of inflammation, blood sugar control, and heart health during treatment and for 5 years afterward.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Center for Clinical Metabolic Research, Gentofte Hospital
Hellerup, Capital Region, 2900, Denmark
Conditions
Explore the condition pages connected to this study.